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Abstract
Background: Silent coronary artery disease (CAD) is prevalent in type 2 diabetes mellitus (T2DM). Although
coronary computed tomography angiography (CCTA) over recent years has emerged a useful tool for assessing and
diagnosing CAD it’s role and applicability for patients with T2DM is still unclarified, in particular in asymptomatic
patients. We aimed to assess the role of CCTA in detecting and characterizing CAD in patients with T2DM without
cardiac symptoms when compared to gold standard invasive coronary angiography (ICA).
Methods: This was a cross-sectional analysis of patients with T2DM without symptomatic CAD enrolled in the Asker
and Baerum Cardiovascular Diabetes Study who, following clinical examination and laboratory assessment,
underwent subsequently CCTA and ICA.
Results: In total 48 Caucasian patients with T2DM (36 men, age 64.0 ± 7.3 years, diabetes duration 14.6 ± 6.4 years,
HbA1c 7.4 ± 1.1 %, BMI 29.6 ± 4.3 kg/m2) consented to, and underwent, both procedures (CCTA and ICA). The
population was at intermediate cardiovascular risk (mean coronary artery calcium score 269, 75 % treated with
antihypertensive therapy). ICA identified a prevalence of silent CAD at 17 % whereas CCTA 35 %. CCTA had a high
sensitivity (100 %) and a high negative predictive value (100 %) for detection of patients with CAD when compared
to ICA, but the positive predictive value was low (47 %).
Conclusions: Low-dose CCTA is a reliable method for detection and exclusion of significant CAD in T2DM and thus
may be a useful tool for the clinicians. However, a low positive predictive value may limit its usefulness as a
screening tool for all CAD asymptomatic patients with T2DM. Further studies should assess the applicability for risk
assessment beyond the evaluation of the vascular bed.
Keywords: Type 2 diabetes mellitus, Cardiovascular complications, Imaging, CT angiography, Coronary artery
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Background
Type 2 diabetes mellitus (T2DM) is a chronic metabolic
disease that represents a major public health concern.
T2DM affects more than 382 million people world-wide
and the prevalence is expected to increase substantially [1].
Cardiovascular (CV) disease is the most common cause of
death in patients with T2DM [2, 3]. The prevalence of un-
diagnosed coronary artery disease (CAD) among asymp-
tomatic patients with T2DM is high and independent
assessments using different diagnostic techniques, i.e., in-
vasive coronary angiography (ICA) [4] or maximum stress-
test [5] have found that more than 1 in 5 adults with
T2DM have significant CAD. The diagnosis of CAD may
be missed or delayed in these patients since the typical
symptoms of CAD are often absent in patients with long-
standing T2DM, which in turn further increases their risk
for CV events. To potentially prevent CV events it may
therefore be important to detect subclinical CAD in
T2DM to enable appropriate intervention to reduce the
risk of fatal and non-fatal cardiac events.
Findings to date to not support widespread screening
for CAD in patients with T2DM, but this may partly be
related to lack of a reliable and cost-effective screening
tool [6].
ICA has been the accepted gold standard method for
assessing the presence, localization, and severity of CAD,
but has a substantial procedural cost and is an invasive
method associated with a risk for complications. Coronary
computed tomography angiography (CCTA) has over
recent years emerged as an alternative to ICA for CAD
assessment and the 64-slice generation scanners multide-
tector computer tomography (MDCT) is now considered
to have high diagnostic performance for detection of sig-
nificant coronary stenosis [7] in different populations. So
far only few studies have assessed the role of MDCT in
patients with T2DM [8, 9], and its full potential is not fully
understood, in particular in light of studies being suggest-
ive of a reduced diagnostic performance of MDCT com-
pared to non-T2DM populations [10]. Thus, the role of
CCTA is considered uncertain in asymptomatic high-risk
patients like patients with T2DM [11].
In this study we aimed to assess the role of CCTA in
detecting and characterizing CAD in patients with
T2DM without cardiac symptoms. To provide robust-
ness of using CCTA, all patients underwent both CCTA
and gold standard ICA, and to our knowledge this is the
first study to employ both strategies in asymptomatic
patients with T2DM.
Methods
Study population
Caucasian subjects with T2DM without cardiac symp-
toms who were enrolled in the Asker and Baerum
Cardiovascular Diabetes (ABCD) study in 2002-2004
[12] and still alive, were eligible for participation in this
7-year cross-sectional follow-up study (ABCD-2). Classi-
fication of subjects as being asymptomatic was based on
patient history and clinical assessment (i.e., free from
cardio-pulmonary symptoms) [13]. In addition to
T2DM, diagnosed in accordance with diagnostic criteria
by the World Health Organization [14], the inclusion cri-
teria in the ABCD-study were age 18-75 years and at least
one additional CV risk factor (hypertension [treated or
24 h systolic/diastolic blood pressure ≥140/90 mmHg],
dyslipidaemia [treated or total cholesterol ≥ 5.0 mmol/L,
HDL-cholesterol ≤1.0 mmol/L in men, or ≤1.1 mmol/L in
women or triglycerides ≥2.0 mmol/L], past or prior smok-
ing, premature CAD in 1st degree family [male < 55 years,
female < 65 years], or microalbuminuria). Exclusion criteria
in this imaging follow-up study were irregular heart rate,
pregnancy, known allergy to iodinated contrast medium
and elevated serum creatinine (female > 120 μmol/L,
male > 130 μmol/L).
The study complied with the Declaration of Helsinki
and was approved by the Regional Committee for Medical
and Health Research Ethics. All participating patients gave
written informed consent.
Investigation and study procedures
Following an assessment of medical history, clinical
examination including cardiopulmonary exercise testing
and laboratory assessment, patients were voluntarily re-
ferred for subsequently assessments with CCTA or ICA
regardless of the results of the non-invasive tests. Both
CAD imaging modalities had to be completed within a
6 month time window by experienced radiologists or
cardiologists.
Cardiopulmonary exercise test
Exercise induced cardiac ischemia was assessed using a
modified conventional maximum symptom-limited 1-min
incremental cardiopulmonary exercise test on a cycle erg-
ometer (Siemens-Elema, Germany). Cycling frequency
had to be at least 60 rounds pr minute. The criterion for
classifying a test as positive was the traditional ≥1 mm ST-
segment depression observed in two adjacent leads.
Laboratory assessment
Peripheral venous blood samples were drawn in the
morning after an overnight fast and routine laboratory
parameters were immediately analyzed by the local la-
boratory. For all assays, the intra-and inter assay coeffi-
cients of variation were <10 %.
Coronary Computed Tomography Angiography (CCTA)
CCTA was performed at Akershus University Hospital,
Lørenskog, Norway, using a 256-slice scanner (Brilliance
iCT, Philips Healthcare, Cleveland, OH, USA). Metoprolol
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was intravenously administered with a titration dose up to
15 mg in all patients with heart rate >70 bpm. A low-dose
scout image followed by unenhanced prospectively ECG-
triggered coronary artery calcium (CAC) scoring acquisi-
tion. Imaging parameters includes X-ray tube voltage
120 kV, detector configuration 32 × 0.625 mm, gantry ro-
tation time 0.33 s, field of view 250 mm, reconstructed
slice thickness 2.5 mm and increment 2.5 mm. Angio-
graphic acquisition was performed using a prospectively
ECG-triggered step-and-shoot mode and the contrast
medium iomeprol (Iomeron 400 mg/ml, Bracco Imaging
SpA). A detector configuration of 128 × 0.625 mm with
dual z-focal spot positions was used. Gantry rotation time
was 0.27 s, temporal resolution 135 msec and X-ray tube
voltage was 120 kV.
Both calcium scoring acquisition and angiographic ac-
quisition were started at a predefined time point at 75 %
of the RR interval corresponding to a physiological phase
of ventricular diastasis, with the tube output turned off
during the other phases of the RR interval. The effective
radiation dose of the CT exam was estimated by the
product of the dose length product from the dose re-
port of the CT scanner and a conversion coefficient
for the chest (k = 0.014 mSv*mGy − 1*cm − 1) [15].
Analysis was performed by two experienced radiologist
in consensus, using specialized software on a dedicated
workstation (Comprehensive Cardiac Analysis, Extended
Brilliance Workspace V4.02, Philips Healthcare, Cleveland,
OH, USA) including semi-automated software for analysis
of Agatston calcium score [16]. The interpreters were
blinded for the results of ICA and non-invasive tests. For
analysis, the coronary arteries were segmented into a 15-
segment American Heart Association (AHA) model [17]
and segments with a luminal diameter ≥1 mm were evalu-
ated. Image quality was ranked using a 4-point scale (1:
good image quality, vessels with sharp edges without dis-
continuity and artifacts; 2: adequate image quality, vessels
with minor artifacts or slight blurring; 3: decreased image
quality, evaluation difficult but still possible; 4: non-
interpretable). Calcifications were ranked using a 3-point
scale (1: no calcifications; 2: minor calcifications; 3: severe
calcifications). All interpretable segments were scored
with a 4-point scale (0: no stenosis or ≤24 % lumen reduc-
tion; 1: 25-49 % stenosis; 2; 50-74 % stenosis; 3: ≥75 %
stenosis). A stenosis of ≥50 % was considered significant.
Invasive coronary angiography
ICA was performed by radial or femoral approach ac-
cording to the standard Judkins technique using 6 F
diagnostic catheters (Cordis Corporation, Miami, FL, USA)
and the contrast medium iodixanol (Visipaque 320 mg/ml,
Amersham Health, GE Healthcare AS, Oslo, Norway). The
angiograms were performed at the catheterization lab at
Oslo University Hospital Rikshospitalet, Oslo, Norway and
analyzed by an experienced cardiologist who was blinded
to the results of non-invasive tests and CCTA. All angio-
grams were evaluated by visual analysis supported by a
quantitative coronary analysis (QCA) program (Sectra
Cardiology Package 1.0, Sectra Imtec, Sweden) with similar
segment model and stenosis grading as for CCTA.
Statistics
Data are reported as frequencies or mean with standard
deviation. Correlations analysis between calcium scores
and baseline HbA1c and duration of T2DM was per-
formed (Spearman’s correlation). Cohen’s kappa statistics
were used to describe concordance between the methods
interpreted by the guidelines of Landis and Koch [18].
Sensitivity, specificity, and positive and negative predict-
ive values with corresponding 95 % confidence intervals
(CI) were calculated for the detection of significant
(>50 %) coronary artery stenoses with CCTA, using ICA
as the gold standard and Vassarstats (Vassar College,
Poughkeepsie, N.Y., USA) for statistical analysis. For all
other statistical analysis, IBM SPSS Version 22 was used.
Results
Demographics
Of 93 patients consenting to participate in ABCD-2, 56
patients had no contraindications to the imaging proce-
dures and consented to perform both CCTA and ICA.
In eight patients CT angiography was not performed, be-
cause of calcium score >1000, rendering 48 patients eli-
gible for analysis. The patient population studied was
obese (mean BMI 29.6 kg/m2) and middle-aged (mean
age 64 years) with a long history of T2DM (mean dur-
ation 15.6 years), not at optimal glycemic control (mean
HbA1c 7.4 %). The majority were males (75 %). Further
characteristics are given in Table 1.
Imaging assessments
In total 99 % (588 out of 594) of coronary segments with a
luminal diameter ≥1 mm from the full patient population
were eligible for analysis with CCTA. Only 6 segments
were non-interpretable, mainly because of severe artifacts
from pacemaker electrodes. Mean Agatston score was
269, but ranged from 0 to 976 and this did not correlate
with neither diabetes duration (r = 0.05, p = 0.75) or
HbA1c (r = -0.14, p = 0.35). Image quality and degree of
calcifications are detailed in Table 2. In analyzing the 588
segments, CCTA had a sensitivity of 90 % (9 of 10) and a
specificity of 96 % (557 of 578) for detection of coronary
stenosis ≥50 % using ICA as gold standard (Table 3). The
positive predictive value was 30 % (9 of 30) and the nega-
tive predictive value 99 % (556 of 557). Degree of stenosis
per segment analysis and maximum degree of any stenosis
per patient analysis are given in Table 3. CCTA wrongly
classified 21 segments (3.8 %) as having significant
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Table 1 Baseline characteristics of the study participants
Number 48
Background information
Gender (male, n (%) 36 (75 %)
Age (years), mean ± SD (range) 64.0 ± 7.3 (41.4–76,7)
Body Mass Index (kg/m2), mean ± SD (range) 29.6 ± 4.3 (21.7–39.7)
T2DM duration (years), mean ± SD (range) 14.6 ± 6.4 (6.8–37.7)
Medical history and medications
History of smoking, n (%) 19 (39.6 %)
Family history of premature CAD (1st degree relative), n (%) 24 (50 %)
Any medication for hypertension, n (%) 36 (75 %)
Any lipidlowering medication, n (%) 38 (79 %)
Any blood glucose lowering medication, n (%) 46 (96 %)
-Any use of insulin, n (%) 9 (18.7 %)
Laboratory and clinically assessment
HbA1c (%), mean ± SD 7,4 ± 1.1
Serum creatinine (μmol/L), mean ± SD (range) 71.4 ± 16.7 (42–117)
Total cholesterol (mmol/L), mean ± SD 4.3 ± 1.0
LDL cholesterol (mmol/L), mean ± SD 2.4 ± 0.8
HDL cholesterol (mmol/L), mean ± SD 1.4 ± 0.4
Triglycerides (mmol/L), mean ± SD 1.3 ± 0.5
Systolic blood pressure (mmHg), mean ± SD 138 ± 17
Diastolic blood pressure (mmHg), mean ± SD 79 ± 8
Heart rate (bpm), mean ± SD 73 ± 13
Exercise ECG
- Positive, n (%)
- Inconclusive, n (%)
- Negative, n (%)
4 (8.3 %)
11 (22.9 %)
33 (68.8 %)
Table 2 Coronary CTA, scan characteristics and results
Number of patients, n 48
Intravenous β-blocker given, n (%) 18 (37.5 %)
Heart rate during scan, mean ± SD (range) 63.7 ± 7.6 (49–88)
Radiation dose (mSv), mean ± SD (range) 3.8 ± 0.7 (2.5–5.0)
Agatston score, mean ± SD (range) 269.0 ± 292.8 (0–976)
Image quality per segment, n (%)
1. Good
2. Adequate
3. Decreased
420 (71 %)
132 (23 %)
36 (6 %)
Degree of calcifications per segment, n (%)
1. None
2. Minor
3. Severe
374 (64 %)
171 (29 %)
43 (7 %)
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stenosis. Of these 21 segments ICA classified 10 segments
with 25-49 % stenosis and the remaining 11 segments
without any stenosis (≤24 % lumen reduction). All these
21 segments were found to have either severe calcifica-
tions or a combination of calcifications and minor artifacts
on CCTA.
In a per patient analysis, 17 % (8 of 48) had at least
one stenosis ≥50 % in any segment at ICA. CCTA cor-
rectly identified all these patients, corresponding to a
sensitivity of 100 %. Specificity was 78 %, positive pre-
dictive value 47 %, and negative predictive value 100 %.
Estimated Kappa was 0,53, giving moderate agreement
between the methods.
At the maximum exercise test, the mean achieved
work capacity was 143 ± 44 Watts. 15 patients (31 %)
had signs of silent ischemia with positive or inconclusive
test. When comparing silent ischemia as detected on the
maximum exercise test versus CCTA and ICA estimated
Kappa were 0,16 and 0,17 respectively, yielding poor
agreement.
Discussion
This study assessed the applicability of using a modern
non-invasive imaging modality to detect significant CAD
in an intermediate CV risk cohort of patients with
T2DM and compared its results with the gold standard
for assessing this, namely ICA. This study, to the best of
our knowledge, is the first that have screened asymp-
tomatic patients with both CCTA and ICA. The main
finding of our study was that 256-slice CCTA with step-
and-shoot technique provides excellent sensitivity and
yields a high negative predictive value for excluding sig-
nificant CAD in patients with T2DM, whereas the speci-
ficity and positive predictive value were lower (78 % and
47 %, respectively). These data are in agreement with re-
sults of other assessments on sensitivities in patients
with low degree of vasculopathy, i.e. low calcium scores
[19]. Our study also shows that the technique provides
good feasibility with nearly all coronary segments eligible
for analysis. Radiation dose is lower than with earlier gen-
eration CT scanners [20] and may be further reduced with
newer techniques like iterative reconstruction [21, 22].
Our data suggested that despite a mean T2D duration of
15 years, mean Agatston score was 269, indicating that
the population still was at intermediate CV risk, and not
too advanced, as one could have expected based on the
lengthy diabetes duration [23].
CCTA is well known to yield many false positives, but
the low positive predictive values in our study seems in-
ferior to most other reports although the results are
varying [24]. There may be several contributions to this.
Positive and negative predictive values are generally in-
fluenced by prevalence of disease, and the low preva-
lence of significant CAD in this study would contribute
to lower positive predictive value than in studies with
higher prevalence. The coronary plaque burden and cor-
onary calcium score are generally higher in diabetic than
in non-diabetic patients [19, 25] and since calcified pla-
ques can lead to overestimation of lesion severity [26]
this may contribute to lower positive predictive value for
CCTA in a diabetic population than in a non-diabetic
population. Some studies have shown smaller coronary
vessel calibre in patients with T2DM as compared to
those without [27, 28], and this may affect the diagnostic
accuracy of CCTA. Reduced diagnostic performance of
CCTA in patients with T2DM is reported in the only
known study comparing with patients without T2DM
[10], but this study included mainly symptomatic pa-
tients and the prevalence of obstructive CAD was high.
On the other side, a mean CAC value of 269 and 18 %
patients with zero CAC score would also render CCTA
a suboptimal test to rule out obstructive CAD among
symptomatic patients [19].
The major established indications for use of CCTA are
within groups of symptomatic patients with low or inter-
mediate pretest probability of obstructive CAD, and in
Table 3 Results of CCTA and ICA
Diagnostic accuracy of CCTA using ICA as gold standard Per segment Per patient
- Sensitivity, % (CI)
- Spesificity, % (CI)
- Positive predictice value, % (CI)
- Negative predictive value, % (CI)
90 % (54–99)
96 % (94–98)
30 % (15–50)
99 % (99–100)
100 % (60–100)
78 % (61–89)
47 % (24–72)
100 % (86–100)
Degree of stenosis n (%), per segment analysis CCTA ICA
0. No stenosis or ≤24 % lumen reduction
1. 25–49 % stenosis
2. 50–74 % stenosis
3. ≥75 % stenosis
447 (76.0 %)
110 (18.7 %)
29 (4.9 %)
2 (0.4 %)
553 (94.0 %)
25 (4.3 %)
9 (1.5 %)
1 (0.2 %)
Maximum degree of any stenosis, n (%), per patient analysis CCTA ICA
0. No stenosis or ≤24 % lumen reduction
1. 25–49 % stenosis
2. 50–74 % stenosis
3. ≥75 % stenosis
10 (20.8 %)
21 (43.8 %)
15 (31.3 %)
2 (4.2 %)
28 (58.3 %)
12 (25.0 %)
7 (14.6 %)
1 (2.1 %)
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some pre- and postoperative settings [11]. A recent
meta-analysis supports the use of CCTA as a first im-
aging test for low- and intermediate-risk patients pre-
senting to the emergency department with chest pain
[29]. The role of CCTA remains uncertain in asymptom-
atic high-risk patients like patients with T2DM, and even
if there are reports finding a prognostic value of CCTA
[8, 9] there is another recent study reporting that use of
CCTA to screen asymptomatic patients with T2DM do
not improve clinical outcome [30]. One study in patients
with T2DM and mild anginal complaints demonstrated
a crucial impact of ischemia on cardiac event rate and
showed a prognostic value of myocardial perfusion scin-
tigraphy (MPS [31], and a possible strategy may be to
perform supplementary MPS in asymptomatic patients
with positive CCTA. Another possible future improve-
ment of screening CCTA may be a combination with
computed tomography myocardial perfusion imaging, as
there are recent promising reports about this method
[32, 33], or to combine results of CCTA with prognostic
biomarkers [34].
The relatively small number of included patients is a
limitation of the generalizability of the study results, in-
cluding the relatively low proportion of female patients.
Conclusions
Low-dose CCTA provides excellent sensitivity and nega-
tive predictive value in detecting and excluding signifi-
cant CAD in patients with T2DM without known or
suspected CAD. The usefulness of this method as a
screening tool in asymptomatic intermediate risk pa-
tients like in T2DM may be limited by a rather low posi-
tive predictive value.
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